GSE171434
Mapping Transcription Factor Nucleosome Dynamics in Plasma
Cell-free DNA (cfDNA) contains a composite map of the epigenomes of its cells-of-origin. Tissue-specific TF binding inferred from cfDNA could enable us to track disease states in humans in a non-invasive manner. Here, we present a method to identify the subset of genome-wide transcription factor binding sites that are protected in plasma. We map binding at tissue-specific sites of constitutive factor CTCF and tissue-specific factors PU.1, LYL1, ER, and FOXA1 in plasma cfDNA. Our method also captures the chromatin structure around the factor-bound sites in their cells-of-origin. We define pure tumor TF signatures in an in vivo model by applying our method to estrogen receptor-positive (ER+) breast cancer xenografts. The tumor-specific cfDNA protections of ER-a and FOXA1 reflect TF-specific accessibility across human breast tumors, demonstrating our ability to capture tumor TF binding in plasma. By modeling cfDNA from cancer donors as a mixture of healthy plasma and pure tumor signatures, we can identify tumor TF binding in humans. Thus, our method enables non-invasive mapping of the regulatory phenotype of cancer in humans. Overall design: sequencing of cell-free DNA extracted from plasma